Friday, 21st March 37th TROG Cancer Research Annual Scientific Meeting 2025

This is open to all ASM delegates (and not catered).

• AI-powered targeted radiotherapy to halve treatment side effects for lung cancer patients - Paul Keall
• Radiotherapy combined with new systemic agents in lung cancer – implications and opportunities - Ken O'Byrne
• Lung Working Party Portfolio Overview - Yu Yang Soon
• Durvalumab after high-dose twice-daily thoracic radiotherapy in limited stage small cell lung cancer. DAHRTS – a randomized phase III trial - Bjørn Grønberg
• Neoadjuvant high precision radiotherapy in NSCLC: Piloting new approaches to improving treatment outcomes and profiling toxicity with 89ZrDurva imaging and cell-free DNA - Fiona Hegi-Johnson
• Evaluating radiotherapy compliance without external quality assurance: an audit from MODERN-LUNG, a phase II multicentre prospective study - Phillippa Gray
• A cost-effectiveness analysis of the TROG 09.02 CHISEL trial. - Adam Byrne
• TROG 17.02 OUTRUN: Randomised phase II trial of Osimertinib with or without stereotactic radiosurgery for EGFR mutated NSCLC with brain metastases - Update (Cat A, Closed) - Yu Yang Soon
• TROG 20.01 CHEST RT: A phase II study of carboplatin and etoposide chemotherapy, durvalumab with or without thoracic radiotherapy in the first line treatment of patients with extensive-stage small-cell lung cancer - Update (Cat A, Follow up) - Eric Hau

• Development of an automated contour quality assurance tool for the TROG 08.08 TOPGEAR trial  - Phillip Chlap
• Initial safety analysis of Pre-operative SRS: a pilot phase 2 study of pre-operative stereotactic radiosurgery for brain metastases - Lucinda Burke
• Imaging biomarkers and quantitative imaging – the new standard for clinical trial end points? - Annette Haworth
• Optimisation of Contralateral and Midline Organs at Risk (OARs) in Tonsil Patients treated with Unilateral Radiotherapy (URT): a Re-optimisation Planning Study from TROG 12.01 - Glen Osbourne
• Cost-effectiveness analysis of radiotherapy alone versus transoral robotic surgery (TORS) for early-stage HPV-associated oropharynx squamous cell carcinoma in Australia - Lan Gao
• Partially ablative radiotherapy versus standard palliative radiotherapy for locally advanced bulky unresectable sarcomas. - Christopher Williams

A grab and go lunch will be available for those needing to leave.